Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Malvidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | CD38 | P28907 | 9/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.68 |
| ▸ | SNCA | P37840 | 3/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | EP300 | Q09472 | 2/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.68 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malvidin SCHEMBL308690 | 1.00 | DPP4 (1.00) | DPP4MAOACD38ALDH1A1TSHR | |
| Malvidin SCHEMBL30683334 | 1.00 | DPP4 (1.00) | DPP4MAOACD38ALDH1A1TSHR | |
| Malvidin SCHEMBL29406694 | 0.99 | CD38 (1.00) | DPP4MAOACD38ALDH1A1TSHR | |
| Malvidin SCHEMBL21739 | 0.99 | CD38 (1.00) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL21649 | 0.96 | CD38 (0.97) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL29947229 | 0.96 | CD38 (0.97) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL30683343 | 0.96 | CD38 (0.97) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL9120043 | 0.94 | CD38 (0.95) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL8411777 | 0.94 | CD38 (0.95) | DPP4MAOACD38ALDH1A1TSHR | |
| Petunidin SCHEMBL21650 | 0.94 | CD38 (1.00) | DPP4MAOACD38ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175003-A1 | MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS | FIRMENICH SA (CH) | 2022-06-09 | — | — | US | claimed |
| US-12409148-B2 | Plant tissue-derived nanoparticles and food powders | PSIGRYPH INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250137169-A1 | PLANT TISSUE-DERIVED NANOFIBRES | PSIGRYPH INC. (CA) | 2025-05-01 | — | — | US | disclosed |
| EP-4125783-B1 | PIGMENT COMPRISING RAPHANUS SATIVUS EXTRACT AND MONTMORILLONITE | GIVAUDAN SA (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12180612-B2 | Plant tissue-derived nanofibres | PSIGRYPH INC. (CA) | 2024-12-31 | — | — | US | disclosed |
| EP-4313022-A1 | NUTRACEUTICAL COMPOSITION COMPRISING INULIN FOR TREATING AND PREVENTING OCULAR DISORDERS OR INTESTINAL MICROBIOTA IMBALANCE | OPHTALMIS (MC) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024022778-A1 | COMBINATION PRODUCT COMPRISING ACTIVE SUBSTANCES SUITABLE FOR ADULT REQUIREMENTS | URGO RECHERCHE INNOVATION ET DEVELOPPEMENT (FR) | 2024-02-01 | — | — | WO | disclosed |
| EP-3082464-B1 | COMPOSITION COMPRISING GRAPE EXTRACTS, THE EXTRACTION METHOD AND ITS USES | MAXIMALISTE LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20230085721-A1 | PIGMENT COMPRISING RAPHANUS SATIVUS EXTRACT AND MONTMORILLONITE | SA, GIVAUDAN (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-4125783-A1 | PIGMENT COMPRISING RAPHANUS SATIVUS EXTRACT AND MONTMORILLONITE | Givaudan SA (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023275142-A1 | FRAGRANCED COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORGANIC ACID ESTER, AN ANTHOCYANI(DI)N DYE AND A FRAGRANCING MATERIAL | L'OREAL (FR) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022200334-A1 | NUTRACEUTICAL COMPOSITION COMPRISING INULIN FOR TREATING AND PREVENTING OCULAR DISORDERS OR INTESTINAL MICROBIOTA IMBALANCE | OPHTALMIS (MC) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022144369-A1 | FRAGRANCED COSMETIC COMPOSITION COMPRISING AN ORGANIC ACID, A NATURAL ANTHOCYANI(DI)N DYE AND A FRAGRANCING MATERIAL, AND PROCESS FOR TREATING KERATIN MATERIALS AND/OR CLOTHING USING THE COMPOSITION | L'OREAL (FR) | 2022-07-07 | — | — | WO | disclosed |
| US-20220175003-A1 | MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS | FIRMENICH SA (CH) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250137169-A1 | PLANT TISSUE-DERIVED NANOFIBRES | ACTB, MMP1, COL2A1 | DPP4 2628/4885MAOA 2346/4885CD38 1774/4885 |
| US-12409148-B2 | Plant tissue-derived nanoparticles and food powders | PCNP, ACTB, VHL | DPP4 2565/4885MAOA 3722/4885CD38 3770/4885 |
| US-20230085721-A1 | PIGMENT COMPRISING RAPHANUS SATIVUS EXTRACT AND MONTMORILLONITE | TYR, RB1, RRP12 | DPP4 4622/4885MAOA 3350/4885CD38 4173/4885 |
| US-12180612-B2 | Plant tissue-derived nanofibres | ACTB, MMP1, COL2A1 | DPP4 2628/4885MAOA 2346/4885CD38 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.